Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.45 |
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.42 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.39 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.37 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30897414 | 0.81 | GAA (0.44) | NOS3NOS1NPFFR1NPFFR2PPARA | |
| SCHEMBL4882935 | 0.81 | NPFFR1 (0.41) | NPFFR1NPFFR2 | |
| SCHEMBL7043632 | 0.80 | NPFFR1 (0.47) | NPFFR1NPFFR2CTSSCTSK | |
| SCHEMBL29598182 | 0.79 | NOS3 (0.45) | NOS3NOS1NPFFR1NPFFR2PPARA | |
| SCHEMBL5846799 | 0.79 | ALDH1A1 (0.52) | EGLN2GPR119MGLLPTPN11CTSS | |
| SCHEMBL3804463 | 0.78 | NPFFR1 (0.46) | NOS3NOS1NPFFR1NPFFR2GPR119 | |
| SCHEMBL3798328 | 0.78 | MIF (0.43) | NPFFR1NPFFR2 | |
| SCHEMBL1457556 | 0.78 | PRSS1 (0.49) | EGLN2PPARA | |
| SCHEMBL17560513 | 0.78 | ABCC9 (0.47) | EGLN2ABCC9KCNJ11PTPN11 | |
| SCHEMBL17560512 | 0.78 | ABCC9 (0.47) | EGLN2ABCC9KCNJ11PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071650-B2 | Vanilloid receptor modulators; analgesic, antiinflammatory and antiulcer effects; such as 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea | PACIFIC CORPORATION (KR) | 2011-12-06 | — | — | US | disclosed |
| US-20080064687-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | SUH YOUNG G | 2008-03-13 | — | — | US | disclosed |
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | PACIFIC CORPORATION (KR) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | TAS2R40, TAS1R2, TAS2R45 | NOS3 871/4885NOS1 753/4885EGLN2 3628/4885 |
| US-20080064687-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | TRPV1, TRPA1, TAS2R5 | NOS3 561/4885NOS1 595/4885EGLN2 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.